ClinicalTrials.gg
Not yet recruitingNCT07393243Updated Feb 6, 2026

Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?

An interventional study of Clear priming of the bypass pump in Ventricular Septal Defect, sponsored by Seattle Children's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 1 Month to 18 Months. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
1 Month to 18 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Heart Septal Defects, Ventricular with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Heart Septal Defects, Ventricular · United States.

Planned enrollment
6th of 14
60 · median 52
Started
2026
the only one that year
No phase
4 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Seattle Children's Hospital

Among the 18 studies in Heart Septal Defects, Ventricular with a site in United States, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 18th registered.

Heart Septal Defects, Ventricular

59 studies on the registry are indexed under Heart Septal Defects, Ventricular; 9 are open to participants now.

Browse Heart Septal Defects, Ventricular studies →

Open to participants now

1 of the 18 studies in Heart Septal Defects, Ventricular with a site in United States is open now.

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Heart Septal Defects, Ventricular studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 1 Month to 18 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Heart Septal Defects, Ventricular with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to study if priming the pump used during cardiac surgery with non-blood fluids instead of donated blood products reduces the inflammation that occurs after heart surgery. The study will focused on pediatric participants who require open heart surgery to repair certain types holes in the heart.

Typically for pediatric patients, the cardiopulmonary bypass pump is "primed" (filled) with donated blood products. This project is going to test if the exposure to these blood products causes inflammation. Patients experience significant inflammation (swelling) after undergoing cardiopulmonary bypass. This inflammation can interfere and slow down the patient's recovery from cardiac surgery. With this project, the investigator are studying if filling the bypass pump with non-blood products reduces the bypass-associated inflammation.

The investigators are also studying if using non-blood fluids to fill the bypass pump reduces bypass associated side effects.

The investigators are also trying to understand how the inflammation starts. The investigators also want to study genetic material called DNA that is collected from a person's blood. Instructions for the body are contained in parts of DNA called genes. Genes determine things like hair and eye color. The investigator hope by studying genes the investigator can learn more about the inflammation that occurs after heart surgery, but the investigators might use participant's genetic information to study other diseases or conditions other the inflammation that occurs after heart surgery.

The investigators will be studying the recovery of 60 participants between 1 month to 18 months of age who require open heart surgery to repair ventricular septal defects (VSDs), a congenital heart defect where there a hole between the lower chambers of the heart.

Participants will:

Allow for information about how the participants recover from surgery to be collected.

Allow blood samples during and after surgery to be collected to understand how the markers of inflammation change between the two groups (blood versus non-blood priming).

Read the detailed description

Cardiopulmonary bypass (CPB) is required for surgical correction/palliation of congenital heart defects. Exposure to CPB results in a robust activation of inflammatory responses. It is now well established that exposure to the CPB circuit is associated with an overwhelming, detrimental systemic inflammatory response. The factors associated with this response may be related to the circuit and exposure to the circuit surface, or may be associated with the body's response to surgical trauma, changes in temperature, etc. Multiple pathways have been shown to be mediating this response, including complement activation, leukocyte activation, endotoxin release, release of oxygen-free radicals, nitric oxide, cytokines, platelet-activation factor, arachidonic acid metabolites and endothelins. Activation of these inflammatory pathways has been implicated in the development of some of the major postoperative complications, such as bleeding tendencies, respiratory insufficiency, renal dysfunction, abnormalities in liver function, and, most seriously, multi-organ failure. Multiple pharmacological therapies have been investigated, with a single aim, to modulate this systemic inflammation. The most widely investigated ones have been corticosteroid administration, use of heparin-coated circuits, leukocyte depletion and ultrafiltration. Despite these efforts, the activation of inflammatory pathways in response to CPB remains a significant clinical problem especially in neonates undergoing CPB.

Over the last several years, several centers including Seattle Children's have been pursuing efforts to restrict the administration of blood products during CPB. In some of the recent publications on the topic, the justifications for moving towards "bloodless CPB" include reducing potential infection risks, consideration that blood products are valuable limited resource, and the concerns of certain religious communities. A limitation of these studies is that they do not examine a patient's clinical course or markers of inflammation in depth. CPB patients experience significant post-CPB inflammation - including increased cytokine levels, inflammatory cell infiltration, vascular leak, and multi-organ dysfunction. In children recovering from complicated cardiac surgeries, increased cytokine levels are associated with high mortality and extended intensive care stays. Typically, a blood-containing prime has been used as a method to preserve high hematocrit levels and maintain oxygen delivery. There are several mechanisms by which exposure to blood products can activate inflammation-which include allergic reactions, cytokines in the blood products, or release of proinflammatory proteins from red blood cells. These mechanisms serve as the basis for the hypothesis that "clear prime" CPB patients will have reduced inflammation as compared to standard of care CPB patients.

Since 5/2021, 174 CPB patients have been operated on at Seattle Children's Hospital (SCH) using restrictive blood management. In 90 of these patients, "bloodless" surgery was attempted. These patients received CPB priming with crystalloid fluids only and without any addition of blood products. These crystalloid fluids are same ones used in current standard of care treatment for pediatric cardiac surgery cases. All other aspects of the patients' treatment were the same including the same bypass machines and tubing. 47 of these patients did not receive blood products during the surgery. 35 patients did not receive any blood products during the hospitalization. There were no statistical differences between the median ventilation time and Intensive Care Unit (ICU) length of stay between the patients operated on with such restrictive blood management as compared to patient controls from our center in which blood products were added to CPB prime.

Dr. Bohuta's recent observational study of 99 SCH neonatal cardiac cases using historical controls identified no statistical difference in postoperative seizures, bleeding events, and lactate levels during CPB between patients who received clear prime versus those who received a blood prime. In this same study, both length of stay and postoperative mechanical ventilation time was shorter in the clear prime group. Hematocrit was consistently lower post-operatively for patients in the crystalloid only group, otherwise, there were no unintended consequences/ adverse events identified in the crystalloid only cohort.

03

Conditions studied

  • Ventricular Septal Defect

Keywords

  • cardiac surgery
  • cardiopulmonary bypass
  • inflammation
  • blood product
04

Who can participate

Ages eligible
1 Month to 18 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight between 5-10kg
  • Age 1-18 months
  • Requiring cardiopulmonary bypass as part of clinically indicated surgery
  • Surgery performed by Dr. Bohuta or Dr. Greene

Exclusion criteria

Exclusion Criteria:

  • /hematocrit too low for clear CPB prime (post-dilution Hct \<24%)
  • Pre-operative ECMO support
  • Active infection
  • Not clinically appropriate for clear prime (instability, arrhythmias, desaturation, etc.)
  • Genetic syndrome
  • Pork allergy or family requests pork avoidance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Blood prime

    The research participants in this arm will undergo their clinically indicated cardiac surgery. The control group will have the bypass pumped primed with mixture of crystalloid solution and blood, which is currently standard of care.

  • Experimental
    Clear prime

    The research participants in this arm will undergo their clinically indicated cardiac surgery. The experimental group will have the bypass pump primed with mixture of crystalloid solution, non-blood fluids.

    Procedure: Clear priming of the bypass pump

Interventions

  • ProcedureClear priming of the bypass pump

    The intervention is priming the pump with non-blood products.

06

What researchers measure

Primary outcomes

  1. Changes in RNA expression of the inflammatory marker TNF-α fold pre-cardiopulmonary bypass (CPB) to 24 hours post-CPB

    Plasma from blood samples collected during four timepoints spanning from pre-CPB to 24 hours post-CPB will be analyzed via RNA-Seq to assess changes in TNF-α fold levels. RNA-Seq measures change in gene expression relative to baseline, with higher relative gene expression indicated higher inflammation.

    Time frame: Up to 24 hours post surgery

  2. Changes in protein expression of the inflammatory marker TNF-α fold pre-cardiopulmonary bypass (CPB) to 24 hours post-CPB

    Plasma from blood samples collected during four timepoints spanning from pre-CPB to 24 hours post-CPB will be analyzed ELISA to assess changes in TNF-α fold levels. ELISA measures concentration in picograms per milliliter, with higher scores indicating more inflammation.

    Time frame: Up to 24 hours post surgery

  3. Changes in RNA expression of the inflammatory marker IL8 fold pre-cardiopulmonary bypass (CPB) to 24 hours post-CPB

    Plasma from blood samples collected during four timepoints spanning from pre-CPB to 24 hours post-CPB will be analyzed via RNA-Seq to assess changes in IL8 fold levels. RNA-Seq measures change in gene expression relative to baseline, with higher relative gene expression indicated higher inflammation.

    Time frame: Up to 24 hours post surgery

  4. Changes in protein expression of the inflammatory marker IL8 fold pre-cardiopulmonary bypass (CPB) to 24 hours post-CPB

    Plasma from blood samples collected during four timepoints spanning from pre-CPB to 24 hours post-CPB will be analyzed via ELISA to assess changes in IL8 fold levels. ELISA measures concentration in picograms per milliliter, with higher scores indicating more inflammation.

    Time frame: Up to 24 hours post surgery

Secondary outcomes

  1. Time to extubation

    Clinical data will be collected to measure the number of hours and minutes post-surgery until participants are extubated.

    Time frame: From intubation until extubation (up to 24 hours post-surgery)

  2. Peak lactic acid levels over the first 24 hours post-surgery

    Clinical laboratory data will be reviewed to identify the highest lactic acid (Normal: ≤2 mmol/L) value recorded within the first 24 hours after surgery. Lactic acid levels (measured in mmol/L) indicate how well the body is delivering oxygen to tissues after surgery.

    Time frame: Up to 24 hours post-surgery

  3. Vasoactive-inotropic score over the first 24 hours post-surgery

    Clinical data will be collected to determine how much ionotropic support is needed during the first 24 hours after surgery. The vasoactive-inotropic score typically range from 0 to 15, with higher scores indicating a greater need for inotropic support and worse outcomes, and values above 15 are considered atypical.

    Time frame: Up to 24 hours post-surgery

  4. Length of hospital stay post-surgery

    Clinical information will be collected from participants' medical charts to measure the length of hospital stay (in days) after surgery.

    Time frame: From the date of surgery until the date of hospital discharge, assessed up to 90 days post-surgery.

07

Study locations

1 site
08

References and documents

Publications

  • Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys Y. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015 Jul;87(7):636-45. doi: 10.1002/cyto.a.22625. Epub 2015 Jan 8. PubMed 25573116 ↗
  • Nellis ME, Karam O, Valentine SL, Bateman ST, Remy KE, Lacroix J, Cholette JM, Bembea MM, Russell RT, Steiner ME, Goobie SM, Tucci M, Stricker PA, Stanworth SJ, Delaney M, Lieberman L, Muszynski JA, Bauer DF, Steffen K, Nishijima D, Ibla J, Emani S, Vogel AM, Haas T, Goel R, Crighton G, Delgado D, Demetres M, Parker RI; Pediatric Critical Care Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding (TAXI-CAB), in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet), and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Executive Summary of Recommendations and Expert Consensus for Plasma and Platelet Transfusion Practice in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding (TAXI-CAB). Pediatr Crit Care Med. 2022 Jan 1;23(1):34-51. doi: 10.1097/PCC.0000000000002851. PubMed 34989711 ↗
  • Burnside JL, Ratliff TM, Kelly MN, Naguib AN, Galantowicz M, Hodge A. Bloodless Arterial Switch Operation in a 2.7-kg Jehovah's Witness Patient. J Extra Corpor Technol. 2020 Jun;52(2):142-145. doi: 10.1182/ject-2000003. PubMed 32669741 ↗
  • Wloch A, Boettcher W, Sinzobahamvya N, Cho MY, Redlin M, Dahnert I, Photiadis J. Bloodless priming of the cardiopulmonary bypass circuit: determinants of successful transfusion-free operation in neonates and infants with a maximum body weight of 7 kg. Cardiol Young. 2018 Oct;28(10):1141-1147. doi: 10.1017/S1047951118001154. Epub 2018 Jul 23. PubMed 30033907 ↗
  • Faraoni D, Meier J, New HV, Van der Linden PJ, Hunt BJ. Patient Blood Management for Neonates and Children Undergoing Cardiac Surgery: 2019 NATA Guidelines. J Cardiothorac Vasc Anesth. 2019 Dec;33(12):3249-3263. doi: 10.1053/j.jvca.2019.03.036. Epub 2019 Mar 20. PubMed 31076306 ↗
  • Wypij D, Jonas RA, Bellinger DC, Del Nido PJ, Mayer JE Jr, Bacha EA, Forbess JM, Pigula F, Laussen PC, Newburger JW. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg. 2008 Feb;135(2):355-60. doi: 10.1016/j.jtcvs.2007.03.067. PubMed 18242268 ↗
  • Tu LN, Hsieh L, Kajimoto M, Charette K, Kibiryeva N, Forero A, Hampson S, Marshall JA, O'Brien J, Scatena M, Portman MA, Savan R, Benner C, Aliseda A, Nuri M, Bittel D, Pastuszko P, Nigam V. Shear stress associated with cardiopulmonary bypass induces expression of inflammatory cytokines and necroptosis in monocytes. JCI Insight. 2021 Jan 11;6(1):e141341. doi: 10.1172/jci.insight.141341. PubMed 33232305 ↗
  • Lam LKM, Murphy S, Kokkinaki D, Venosa A, Sherrill-Mix S, Casu C, Rivella S, Weiner A, Park J, Shin S, Vaughan AE, Hahn BH, Odom John AR, Meyer NJ, Hunter CA, Worthen GS, Mangalmurti NS. DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia. Sci Transl Med. 2021 Oct 20;13(616):eabj1008. doi: 10.1126/scitranslmed.abj1008. Epub 2021 Oct 20. PubMed 34669439 ↗
  • Bohuta L, Charette K, Chan T, Joffe D, Koth A, Greene CL, Mauchley D, McMullan DM. Encouraging results of blood conservation in neonatal open-heart surgery. J Thorac Cardiovasc Surg. 2024 Mar;167(3):1154-1163. doi: 10.1016/j.jtcvs.2023.07.032. Epub 2023 Jul 29. PubMed 37517580 ↗
  • Bozza MT, Jeney V. Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs. Front Immunol. 2020 Jun 30;11:1323. doi: 10.3389/fimmu.2020.01323. eCollection 2020. PubMed 32695110 ↗
  • Appachi E, Mossad E, Mee RB, Bokesch P. Perioperative serum interleukins in neonates with hypoplastic left-heart syndrome and transposition of the great arteries. J Cardiothorac Vasc Anesth. 2007 Apr;21(2):184-90. doi: 10.1053/j.jvca.2006.02.027. Epub 2006 May 30. PubMed 17418729 ↗
  • Kato H, Chasovskyi K, Gandhi SK. Are Blood Products Routinely Required in Pediatric Heart Surgery? Pediatr Cardiol. 2020 Jun;41(5):932-938. doi: 10.1007/s00246-020-02338-7. Epub 2020 Mar 13. PubMed 32170329 ↗
  • Boettcher W, Sinzobahamvya N, Miera O, Redlin M, Dehmel F, Cho MY, Murin P, Berger F, Photiadis J. Routine Application of Bloodless Priming in Neonatal Cardiopulmonary Bypass: A 3-Year Experience. Pediatr Cardiol. 2017 Apr;38(4):807-812. doi: 10.1007/s00246-017-1585-x. Epub 2017 Feb 14. PubMed 28197644 ↗
  • Naguib AN, Winch PD, Tobias JD, Simsic J, Hersey D, Nicol K, Preston T, Gomez D, McConnell P, Galantowicz M. A single-center strategy to minimize blood transfusion in neonates and children undergoing cardiac surgery. Paediatr Anaesth. 2015 May;25(5):477-86. doi: 10.1111/pan.12604. Epub 2015 Jan 12. PubMed 25581204 ↗
  • Klein HG. Immunomodulatory aspects of transfusion: a once and future risk? Anesthesiology. 1999 Sep;91(3):861-5. doi: 10.1097/00000542-199909000-00040. No abstract available. PubMed 10485799 ↗
  • Mou SS, Giroir BP, Molitor-Kirsch EA, Leonard SR, Nikaidoh H, Nizzi F, Town DA, Roy LC, Scott W, Stromberg D. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med. 2004 Oct 14;351(16):1635-44. doi: 10.1056/NEJMoa041065. PubMed 15483282 ↗
  • Holmes JH 4th, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF, Hall RA. Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res. 2002 Dec;51(12):579-86. doi: 10.1007/pl00012432. PubMed 12558191 ↗

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD) that underlie results in publication will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: At the time of publication, deidentified IPD will be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Dec 2028, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Feb 6, 2026
StartEst.
Feb 25, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393243
Responsible party
Vishal Nigam (Attending Physician, Seattle Children's Hospital) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 25, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Feb 6, 2026

Study contacts

Stephanie A Lammers, BSN
Contact
stephanie.lammers@seattlechildrens.org
2069875916
Kira A Spencer, PhD
Contact
kira.spencer@seattlechildrens.org
206-987-2000
Vishal Nigam, MD
principal investigator · Seattle Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion